The European Organization for Research and Treatment of Cancer (EORTC) conducted a prospective phase II study (EORTC 90101 CREATE) that included a subcohort of ALK-positive IMT patients treated with crizotinib. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.